Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target
Score
Phathom Pharmaceuticals, Inc. price target
| PHAT | |
|---|---|
| Low | $10.00 |
| Average | $16.50 |
| High | $22.00 |
| Upside vs current price | +172.3% |
The average target of $16.50 is +172.3% versus the current PHAT price of $6.06.
Phathom Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 8 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
11 analysts cover PHAT.
Phathom Pharmaceuticals, Inc. EPS and revenue estimates
The estimate table for the Phathom Pharmaceuticals, Inc. keeps 2026 EPS $-0.74, 2027 EPS $0.66, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.74 | $315.03M |
| 2027 | $0.66 | $488.03M |
Is Phathom Pharmaceuticals, Inc. a buy or sell?
Of the 11 analysts covering Phathom Pharmaceuticals, Inc., 10 rate it a buy (2 strong buy and 8 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The PHAT consensus label is Buy, beside 10 buy-side ratings and 0 sell-side ratings.
The average target of $16.50 implies +172.3% versus the current price of $6.06.
the Phathom Pharmaceuticals, Inc. closes with 10 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Phathom Pharmaceuticals, Inc. forecast
Analysts are far apart on PHAT. The published low is $10.00, the average is $16.50, and the high is $22.00.
From today's $6.06 print, the PHAT average target is +172.3% away.
Most of the PHAT coverage agrees: 10 of 11 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
PHAT targets have been marked up: $15.50 across the last month versus $13.75 across the last quarter.
PHAT coverage is thin at 11 analysts, and one revision moves the average.
Phathom Pharmaceuticals, Inc. forecast questions
What is the PHAT price target?
The published range for PHAT is $10.00 to $22.00, with an average of $16.50. That average is +172.3% versus the current price of $6.06.
Is Phathom Pharmaceuticals, Inc. a buy or sell?
Of the 11 analysts covering Phathom Pharmaceuticals, Inc., 10 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, which for PHAT is 10 on the buy side, 1 at hold, and 0 on the sell side.
What is the EPS estimate for Phathom Pharmaceuticals, Inc.?
Analyst EPS estimates for Phathom Pharmaceuticals, Inc.: 2026 $-0.74, 2027 $0.66.
What is the revenue estimate for Phathom Pharmaceuticals, Inc.?
Analyst revenue estimates for Phathom Pharmaceuticals, Inc.: 2026 $315.03M, 2027 $488.03M.
How many analysts cover PHAT?
11 analysts cover PHAT. Their consensus on PHAT is Buy, across those 11.